Freestone Grove Partners’s Bio-Techne TECH Stock Holding History

Freestone Grove Partners’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-820,072	Closed	-$42.9M	–	1317
2026 Q1	$42.9M	Buy	+820,072	New	+$49.2M	0.3%	111
2025 Q4	–	Sell	-711,980	Closed	-$39.6M	–	940
2025 Q3	$39.6M	Buy	+711,980	New	+$38.1M	0.3%	123
2025 Q1	–	Sell	-417,143	Closed	-$30M	–	780
2024 Q4	$30M	Buy	+417,143	New	+$30.6M	0.37%	95

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Freestone Grove Partners's TECH Position: Q2 2026 in Review

Freestone Grove Partners sold out of Bio-Techne (TECH) in Q2 2026, closing a stake of 820,072 shares — an estimated $42.9M sold.

Freestone Grove Partners first reported a position in TECH in Q4 2024 and held it in 3 quarters. The position peaked at $42.9M in Q1 2026. 596 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

Freestone Grove Partners reported no remaining Bio-Techne position as of Q2 2026 after selling out during the quarter.
Freestone Grove Partners sold 820,072 Bio-Techne shares in Q2 2026, an estimated $42.9M.
Freestone Grove Partners first reported a position in Bio-Techne in Q4 2024 and held it in 3 quarters.
Freestone Grove Partners's Bio-Techne position peaked at $42.9M in Q1 2026.
596 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.